TLX101-Px (Pixlumi®) MAA Accepted in Europe
MELBOURNE, Australia and INDIANAPOLIS, May 1, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the marketing authorization application (MAA) filed in Europe for TLX101-Px (O-(2-fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate, has been validated and accepted for review. The application, covering commercially significant European markets, has...
TraceLink Wins 2026 Globee® Cybersecurity Award as OPUS Sets the Standard for Secure, Agentic Supply Chain Operations
GxP-aligned, industrial-grade platform secures the world's largest Agentic Business Network—enabling trusted, real-time execution across global supply chains SummaryTraceLink has been named a winner in the 2026 Globee® Awards for Cybersecurity, recognizing the company's leadership in securing complex, multienterprise supply chain operations. TraceLink's Orchestration Platform for Universal Solutions (OPUS) is a GxP-aligned,...
Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis
- Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of atopic dermatitis (AD) and other type 2 inflammatory skin diseases - - Bambusa plans to announce topline results from the placebo-controlled Phase 1b/2a trial of...
For the Reasons that Matter: A First‑of‑Its‑Kind Multi-Country Campaign Spotlights Adult Respiratory Health
A first-of-its-kind multi-country adult respiratory health awareness campaign is now live across Singapore, Malaysia, Indonesia, and the Philippines SINGAPORE, April 30, 2026 /PRNewswire/ -- In conjunction with World Immunisation Week, Pfizer Singapore, together with healthcare professionals, has launched "For the Reasons that Matter", a public awareness campaign focused on adult respiratory health. Rolling out simultaneously across Singapore, Malaysia, Indonesia...
Malaysia Healthcare Strengthens Presence in Myanmar as Demand for Trusted Treatment Abroad Grows
KUALA LUMPUR, Malaysia, April 30, 2026 /PRNewswire/ -- For many patients in Myanmar, seeking medical care abroad is becoming an increasingly considered decision, particularly for specialised treatments, second opinions, and long-term health management. As healthcare awareness grows, more patients are looking beyond borders for greater assurance in diagnosis, access to advanced medical technologies, and comprehensive care pathways. ...
Huahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug HH160
BEIJING, April 30, 2026 /PRNewswire/ -- Huahui Health today announced that it has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a novel trispecific antibody in oncology immunotherapy. Under the agreement, BeOne Medicines is granted an exclusive option covering the development, manufacturing, and commercialization of HH160 worldwide. Pursuant to the agreement, BeOne Medicines will pay Huahui...
Ascendion Recognized Among India’s Top 50 Best Workplaces in Health & Wellness for the Third Consecutive Year
BENGALURU, India, April 30, 2026 /PRNewswire/ -- Ascendion, an AI-native software engineering company, has been recognized among the Top 50 of India's Best Workplaces™ in Health & Wellness 2026: Companies That Care, marking its third consecutive year on the list. Ascendion, an AI-native software engineering company, has been recognized among the...
Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases
SINGAPORE and TAIPEI, April 30, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. ("Formosa", 6838.TW) and the Singapore Eye Research Institute ("SERI") are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa's proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI's world-class clinical research expertise, led...
New Classification System of Malocclusions Published in the Journal of Aligner Orthodontics (JAO) by Prof. Gang Shen’s Team
SHANGHAI, April 30, 2026 /PRNewswire/ -- A seminal research paper titled "A New Classification System for Malocclusions with Facial Convexity" has been officially published in the 2026 Volume 1 issue of the Journal of Aligner Orthodontics (JAO). This article, authored by Professor Gang Shen and his orthodontic team, introduces a transformative diagnostic framework. Building upon the traditional Angle classification system categorizes and...
Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine
HONG KONG and HANGZHOU, China, April 30, 2026 /PRNewswire/ -- Hangzhou Diagens Biotech Co., Ltd. (HKEX: 2526, "Diagens"), a pioneer in medical imaging foundation models, today announced its first annual results since its listing. The report marks a pivotal milestone in the company's transition from technical validation to large-scale commercialization, with annual revenue reaching RMB 164 million, a year-on-year...
